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Abstract: Prior to 2011, the 1-year survival rates for patients suffering from advanced or 
metastatic melanoma was as low as 33%, with a median overall survival of about 9 months. 
Several chemotherapeutic regimens have been applied, either as monochemotherapy or as poly-
chemotherapy, overall not resulting in an improvement of progression-free or overall survival. 
Novel insights into the epidemiology and biology of melanoma allowed the development of 
newer therapies. The discovery of mutations in BRAF, a part of the mitogen-activated protein 
kinase, allowed the development of two BRAF inhibitors, vemurafenib and dabrafenib, which 
significantly improved the outcome of metastatic melanoma treatment. This article reviews 
the mechanism of action, efficacy, and safety profile of dabrafenib. An in-depth knowledge of 
this medication will encourage clinicians to select the appropriate therapeutic strategy for each 
patient, as well as to prevent or adequately manage side effects, optimizing, thus, the drug’s 
applicability.
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Introduction
Despite an increase in the incidence of advanced melanoma, little progress has 
been made over recent decades in addressing the poor prognosis of patients or the 
limited treatment options available.1–3 The “traditional” treatments for metastatic 
melanoma were associated with low response rates and complicated by severe tox-
icities. Dacarbazine was one of the first chemotherapies approved for metastatic 
melanoma, achieving a response rate of about 20% and a median response duration of 
5–6 months. However, studies assessing the efficacy of dacarbazine revealed no benefit 
in overall survival (OS).4 High-dose interleukin (IL)-2 has been reported to achieve a 
6%–16% response rate, with a progression-free survival (PFS) of 13.1 months.5,6 How-
ever, the response rate of IL-2 in patients with brain metastasis is only 5%.7 A slightly 
improved response rate and PFS has been reported with the combination of high-dose 
IL-2 therapy and the peptide vaccine gp-100. However, the use of high-dose IL-2 is 
restricted by its severe toxicity, consisting of capillary leak syndrome, arrhythmias, 
hypotension, and neurologic disturbances.5,6 Although lacking an OS benefit and associ-
ated with severe toxicity, IL-2 remained for years a first-line treatment for metastatic 
melanoma, on the basis of the prolonged PFS of responding patients.5 Temozolomide 
is an oral alkylating agent with a cytotoxic effect similar to dacarbazine. Based on its 
ability to penetrate the blood–brain barrier, temozolomide has been tested in previ-
ously untreated patients with brain metastases, achieving a response rate of ~7% and 
a median PFS of 1.2 months.8 Combination chemotherapy has also been tested in 
several studies, without showing any improvement in response rates.9
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During the last years, the prognosis of metastatic 
melanoma substantially changed with the introduction of 
kinase inhibitors vemurafenib, dabrafenib, and trametinib and 
the immune checkpoint inhibitor ipilimumab, an anti-CTLA-4 
antibody.10–13 More recently, clinical trials testing the efficacy 
of the programmed cell death-1 receptor inhibitors nivolumab 
and pembrolizumab showed a further improvement in OS of 
metastatic melanoma patients.7,8
Targeted therapy
Several key genetic mutations have been shown to contribute 
to melanoma development and progression. Approximately 
40%–50% of melanomas harbor activating mutations in the 
BRAF oncogene, most of them found in exon 15, codon 600 
(V600). The most frequent mutation event is the substitution 
of valine by glutamic acid (V600E), occurring in ~75% of 
the cases. Other, less frequent, substitutions include valine 
by lysine (V600K) and valine by arginine (V600R).
BRAF is a key molecule of the rat sarcoma gene (RAS), 
which activates several pathways, such as the mitogen-
activated protein kinase (MAPK) pathway that induces cell 
growth and cell proliferation. Indeed, mutations in the MAPK 
signaling pathway may be detected in melanoma patients.14 
Intracellular signaling is triggered by growth factors that 
enhance the binding of a GTP protein (RAS) to cell mem-
branes, which, subsequently, promotes the formation of dim-
ers leading to the activation of RAF kinases.15 RAF kinases 
stimulate the phosphorylation of MEK proteins, which in 
turn phosphorylate and activate the protein kinase ERK. 
ERK, finally, stimulates the signals for progrowth within 
the nucleus, leading to cell proliferation and differentiation 
and to an inhibitory feedback toward upstream components 
of the pathway.15–17 Therefore, the uncontrolled activation of 
the MAPK pathway is associated with the proliferation of 
malignant cells. This pathway is physiologically activated 
when extracellular signals bind to their cognate membrane 
receptor, typically a receptor tyrosine kinase.
BRAF mutations have been reported also in most of the 
melanocytic nevi, suggesting that the mutation is not respon-
sible for malignancy in melanocytic proliferations. This 
indicates that BRAF mutations may contribute to an early 
increased proliferation of melanocytes, but not necessarily 
a malignant transformation.10 In fact, the formation of nevi 
might result from melanocytic proliferation driven by BRAF 
mutations and followed by oncogene-induced senescence. 
In contrast, melanoma formation requires that senescence 
does not occur.18–20 Most melanoma cells derive directly 
from transformed melanocytes, without a previous formation 
of a nevus, possibly resulting from other genetic alterations 
(eg, alterations in the p53 and Rb pathways) additional to 
the oncogenic BRAF mutations.
BRAF mutations in melanoma are significantly more fre-
quent in younger patients, while BRAF mutational status has 
been shown to correlate to the anatomic site of primary mela-
noma, the histological subtype, the evidence of chronic sun 
damage and, partially, the geographic region (Table 1).21,22 
For example, BRAF mutations are much less frequent in 
acral and mucosal melanoma, while they have never been 
documented in uveal melanoma.23,24
Two different combinations of BRAF inhibitors have been 
developed and tested for advanced melanoma: type 1 BRAF 
kinase inhibitors, which bind and inhibit the effect of BRAF 
mutation, and type 2 BRAF inhibitors, binding to the inac-
tive kinase.17 Wild-type BRAF status represents an absolute 
contraindication for such compounds, due to paradoxical 
activation of MAPK.15
Sorafenib, a nonselective BRAF inhibitor, acts as a 
pan-inhibitor of BRAF and has largely failed in melanoma 
treatment. In contrast, drugs that selectively target a mutated 
and activated form of the BRAF kinase have been shown to 
be appropriate for BRAF mutant melanoma treatment.
Vemurafenib (Zelboraf®) was the first molecular agent 
targeting the mutated BRAF kinase that demonstrated an 
improved OS in a Phase III randomized trial. Vemurafenib 
is an orally administered small-molecule showing a remark-
able antitumor activity against BRAFV600E mutant mela-
noma cell lines. On the basis of the documented efficacy 
of vemurafenib in Phase I and II studies,17,25 a Phase III 
randomized clinical trial (BRIM-3) compared vemurafenib 
to dacarbazine in patients with unresectable stage III or IV 
melanoma.26 In this trial, 675 previously untreated patients 
with BRAFV600E mutation-positive advanced melanoma 
were randomized to receive either 960 mg of vemurafenib 
orally twice a day or 1 g/m2 of dacarbazine intravenously 
Table 1 Frequency, type, and clinical characteristics associated to BRAF mutation
Cancer type Mutation frequency and type Clinical characteristics
Melanoma 46%–48%; v600e more common than v600K;  
other rare exon 15 mutations reported
BRAFV600E mutations more common in younger persons  
and in tumors arising from intermittently sun-exposed skin. 
Mutually exclusive with NRAS
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every 3 weeks. The endpoints of the study were PFS and OS. 
After a median follow-up period of 3.8 months for patients 
treated with vemurafenib and 2.3 months for those receiv-
ing dacarbazine, vemurafenib was associated with a rela-
tive reduction of 63% in the risk of death and of 74% in 
the relative risk of disease progression, as compared with 
dacarbazine (P,0.001). Vemurafenib was also associated 
with a higher disease control rate and a higher response rate. 
The safety and efficacy of vemurafenib and dacarbazine in 
this Phase III study were updated at a median follow-up of 
12.5 and 9.5 months, respectively, with median OS reach-
ing 13.6 months with vemurafenib compared to 9.7 months 
with dacarbazine. The hazard ratio (HR) for death in the 
vemurafenib group was 0.70 (95% confidence interval [CI]: 
0.57–0.87; P=0.0008).10 The vemurafenib group showed 
significantly longer PFS than the dacarbazine group (6.9 
vs 1.6 months; HR 0.38 (95% CI: 0.32–0.46); P,0.0001). 
The relative impact of vemurafenib with respect to mutated 
BRAF subtypes was also assessed by the updated analysis, 
showing comparable efficacy and toxicity in patients with 
BRAFV600E and BRAFV600K mutation.10
The recommended dose of vemurafenib is 960 mg to 
be taken orally twice each day. The most common adverse 
events (AEs) recorded in the BRIM-3 registration trial 
included arthralgia, fatigue, nausea, rash, photosensitivity, 
and development of cutaneous squamous cell carcinoma 
(cSCC) or keratoacanthoma (KA) (25).10 The most frequent 
grade 3 or 4 AEs were cSCC/KA, transaminitis, and rash.14 
The dose of vemurafenib was modified or interrupted due to 
AEs in 38% of patients,26 while the drug was permanently 
discontinued in only 7% of the patients treated.10
The second selective BRAF inhibitor approved for treat-
ment of BRAF-mutated metastatic melanoma is dabrafenib 
(Tafinlar®), which is a highly potent adenosine triphosphate-
competitive inhibitor of BRAFV600E kinase with proven 
antitumor activity within the brain and systemically. The 
recommended dose is 150 mg twice a day.
Dabrafenib monotherapy
The approval of dabrafenib was mainly based on the BREAK 
trial, which began in 2009; the initial results of the Phase I 
trial were presented in 2010 and the final results in 2012.19,20 
The trial in Phase I included 184 patients, 156 suffering from 
melanoma and 28 from other solid tumors, with an Eastern 
Cooperative Oncology Group performance status of 0 or 1. 
The main aim of the study was to evaluate the safety and 
tolerability of dabrafenib, as well as to determine the recom-
mended dose for Phase II. Secondary aims were to investigate 
the pharmacokinetic/pharmacodynamic profile of the drug 
and the tumor response. The treatment was continued until 
disease progression, intolerable toxic events, or withdrawal 
of consent. The tumor response was assessed by the Response 
Evaluation Criteria in Solid Tumours version  1.0. The most 
common AEs included development of cSCC (20 patients, 
11%), fatigue (14, 8%), and pyrexia (11, 6%). A reduction in 
drug dose was required in 13 (7%) patients, while no deaths 
or discontinuations due to AEs occurred. On the basis of 
safety and the pharmacokinetic profile of dabrafenib, the dose 
of 150 mg twice daily was determined as the recommended 
dose for Phase II. Among the 36 patients with BRAFV600-
mutant melanoma receiving the recommended dose, 18 
(50%, 32.9–67.1 CI 95%) had confirmed response, while the 
response rate for patients with BRAFV600E was 56% (15 out 
of 27, 56%, 35.3–74.5).27 The median duration of response 
was 6.2 months (95% CI, 4.2–7.7) and the PFS was similar 
for patients with BRAFV600E and V600K mutations (5.5 and 
5.6 months, respectively).
After establishment of the optimal dose, three expanded 
cohorts were added; one with metastatic melanoma, one 
with asymptomatic untreated brain metastases (3 mm or 
larger), and one with nonmelanoma solid tumors. In the 
BREAK-2, single-arm, open-label, Phase II trial, 76 patients 
with melanoma and BRAFV600E and 16 with BRAFV600K 
mutation were enrolled.28 The response rate was much bet-
ter in the V600E group (59% with 7% complete response) 
than the V600K group (13%). PFS and OS were also longer 
in the V600E group (6.3 and 13.1 months, respectively), 
compared to patients with V600K (4.5 and 12.9 months, 
respectively).
Although the different response between patients har-
boring the V600E and those with V600K mutation cannot 
be adequately explained, it provides evidence supporting 
that these genotypes correspond to biologically distinct 
subtypes of melanoma, with V600K mutation associated with 
a significantly shorter disease-free interval but no difference 
in survival thereafter.22
In the Phase I study, a reduction in the size of brain 
metastases was reported in nine of ten patients, four of whom 
experienced a complete remission.19 Based on this observa-
tion, the BREAK-MB Phase II study was designed to assess 
the efficacy of dabrafenib in patients with BRAFV600E-
mutant melanoma with untreated or recurrent/progressing 
after local treatments on brain metastases. The study found 
dabrafenib to be effective in both groups of patients (with 
previously treated brain metastasis and untreated ones). 
The reported survival was approximately three times longer 
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compared to the temozolomide study (patients were not 
BRAF genotyped).8,29 The safety profile was acceptable; 
the three most frequent serious AEs were pyrexia (6%), 
intracranial hemorrhage (6%, one treatment related), and 
development of cSCC (6%).
The pivotal Phase III trial11 (BREAK-3) compared dab-
rafenib with dacarbazine (DTIC) in patients with stage IV 
or unresectable stage IIIC BRAFV600E melanoma with an 
Eastern Cooperative Oncology Group performance status 
of 0 or 1. The trial enrolled patients with a 3:1 randomiza-
tion to receive either dabrafenib 150 mg or DTIC (1,000 
mg/m2 every 3 weeks). Patients receiving DTIC crossed 
over to dabrafenib in case of disease progression. The 
primary endpoint of the study was PFS as assessed by a 
local investigator. Secondary endpoints were the follow-
ing: PFS assessed by an independent review committee 
(IRC); OS; objective response rate (ORR) according to 
revised Response Evaluation Criteria in Solid Tumours 
guidelines, version 1.1,30 as assessed by an investigator 
and IRC; PFS after crossover from DTIC to dabrafenib, 
response duration, quality of life, safety, and tolerability. 
Confirmed responses by an IRC were recorded in 50% of 
dabrafenib patients (3% complete, 47% partial) and 6% of 
DTIC patients (2% complete, 4% partial). The median time 
to response in the dabrafenib group was 6.2 weeks. Similarly 
to the previous vemurafenib Phase III trial, a median PFS 
of 6.9 months was found for dabrafenib treatment versus 
2.7 months for DTIC.
The most recent update at 16.9 months median follow-
up31 reported a median OS of 20.0 months for dabrafenib 
versus 15.6 months for DTIC (59% of DTIC patients crossed 
over to dabrafenib arm). Of note, 18 patients (10%) remain 
on dabrafenib without disease progression.
Toxic AEs and cSCC are reported less frequently in 
patients treated with dabrafenib compared to those treated 
with vemurafenib, but a direct comparison has never been 
conducted.
Dabrafenib in combination
Although BRAFi were the first agents achieving a significant 
efficacy in metastatic melanoma, their beneficial effect is 
limited by the frequent development of acquired resistance, 
while ~15% of patients do not respond at all. Therefore, 
several challenges remain to be addressed to optimize the 
efficacy of these drugs and minimize treatment failures. 
Resistance to targeted therapy with BRAFi is a result of 
reactivation of the MAPK pathway, limiting the PFS benefit 
to 6–8 months. BRAF inhibitors have also been suggested 
to induce secondary primary tumor development through a 
paradoxical activation of the MAPK pathway in cells lacking 
BRAF mutations.
The estimated crucial role of the MAPK pathway in the 
development of resistance to BRAFi generated the hypothesis 
that its blockage by an MEK inhibitor might improve the 
efficacy of BRAFi. This led to the first combination treatment 
of a BRAF inhibitor (dabrafenib) with an MEK inhibitor 
(trametinib). Trametinib, an MEK1/2 inhibitor targeting the 
kinase downstream of BRAF in the MAPK pathway, is also 
active in monotherapy in BRAF-mutated melanomas but 
with lower efficacy than BRAF inhibitors. As opposed to 
dabrafenib, the metabolism of trametinib is predominantly 
nonhepatic, involving deacetylation as well as secondary 
modifications including oxidation and glucuronidation. 
Trametinib does not appear to have significant inhibitory 
activity toward CYP isozyme or transport proteins, limiting, 
thus, the possibility of interactions with dabrafenib.
The efficacy of the combination treatment has been 
tested in different schemes, including synchronous and 
sequential initiation of the two agents. It has been shown 
that inhibition of MEK by a single agent has limited value 
in patients with melanoma after progression on a BRAF 
inhibitor.32 Instead, the response rate to MEK inhibition 
was higher when this agent was given first, followed by the 
initiation of dabrafenib.12 However, all sequential regimens 
were shown to be inferior to the synchronous initiation of 
the two drugs.
Analytically, a Phase I/II study explored the combina-
tion of dabrafenib and trametinib in patients affected by 
advanced melanoma harboring mutations in BRAFV600E/K. 
Combination treatment with 150 mg of dabrafenib twice 
per day and 2 mg of trametinib daily was compared with 
monotherapy with 150 mg of dabrafenib twice per day. 
A significantly higher response rate (76% vs 54%, P=0.03) 
and a prolonged PFS was observed in the combination arm, 
compared to dabrafenib monotherapy.33 Furthermore, com-
bination therapy was associated with a lower rate of cSCC 
development (7% vs 19%), whereas pyrexia was more fre-
quent in the combination arm (71% vs 26%). Based on these 
promising data, US Food and Drug Administration approved 
the combination treatment of dabrafenib and trametinib for 
metastatic melanoma. Subsequently, the superiority of the 
combination regimen was further documented by the results 
of two Phase III trials. In COMBI-V study,34 dabrafenib plus 
trametinib were compared to vemurafenib plus placebo as 
first-line treatment for BRAF-mutant metastatic melanoma. 
The study was terminated early since, at the preplanned 
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interim analysis, the combination treatment was assessed as 
significantly superior. In detail, patients receiving the com-
bination treatment had a longer OS (median OS not reached 
vs 17.2 months), a longer PFS (11.4 vs 7.3 months; HR 0.56 
[95% CI 0.46–0.69]; P,0.001), a prolonged response dura-
tion (13.8 vs 7.5 months) and a higher response rate (64% vs 
51%; P,0.001).35 The last data cutoff was then performed at 
349 events, with the combination treatment associated with a 
higher 2-year OS compared to vemurafenib (51% and 38%, 
respectively), a higher median OS (25.6 vs 18.0 months (HR 
0.66; P,0.001), a prolonged PFS (12.6 vs 7.3 months, HR 
0.61; P,0.001), and improved ORR and deep of response. 
Good prognostic features at baseline, associated with durable 
response and prolonged OS, were the following: lactate 
dehydrogenase, with a 2-year OS rate of 66% and a median 
PFS of 17.5 months, earlier-stage melanoma, and fewer 
metastatic sites.36
Furthermore, this study showed that treatment with the 
combination of dabrafenib plus trametinib does not result in 
deterioration of quality of life, adding a clear benefit over 
monotherapy with the BRAF inhibitor vemurafenib.34 The 
latter finding is highly relevant in clinical practice, since, in 
addition to the survival benefit, the minimization of disease-
associated symptoms and drug-associated AEs also represent 
pursued goals.
In the second Phase III study, COMBI-D, untreated 
BRAF-mutant patients were randomized to receive either 
dabrafenib and trametinib or dabrafenib plus placebo. The 
median OS for the combination group was 25.1 months (95% 
CI 19.2 to not reached) versus 18.7 months (15.2–23.7 95% 
CI) for the monotherapy group, while 1- and 2-year survival 
rates were also higher in the combination group. Among 
patients receiving the combination of dabrafenib, 87% expe-
rienced treatment-related AEs, compared to 90% of patients 
in the dabrafenib group. Fever was the most common AE 
(52%) in the combination group and hyperkeratosis (33%) in 
the monotherapy group, while grade 3 or 4 AEs were similar 
in the two groups (32% and 31%).37
Finally, a Phase III randomized, double-blind and 
placebo-controlled trial (COMBI-AD) is underway, assessing 
the efficacy of the combination of dabrafenib plus trametinib 
as an adjuvant therapy, following surgical excision, of high-
risk BRAF mutation-positive melanoma (NCT0909453).
Since targeted therapy has an important effect on the 
immune system, the possibility of combining a BRAF or MEK 
inhibitor with immunotherapy is an interesting approach. 
However, Phase I data showed that combined administration of 
vemurafenib and ipilimumab increases liver toxicity (although 
this was not reported with dabrafenib plus ipilimumab),38 while 
the triple combination of ipilimumab plus dabrafenib and tra-
metinib was reported to increase the risk of bowel perforation. 
The development of anti-PD-1/PD-L1 agents, which appear to 
be more effective and less toxic than ipilimumab, reintroduces 
the possibility of a combined approach with BRAF or MEK 
inhibitor. Indeed, a Phase I study reported data on the combina-
tion of the anti-PD-L1 antibody, MEDI14736 (durvolumab) 
with dabrafenib and trametinib in patients with clinical stage 
IIIC or stage IV melanoma. The triple combination resulted 
in an ORR of 69% and disease control rate of 100%, showing 
also a manageable safety profile. However, longer follow-up 
will be necessary to determine the efficacy and safety of the 
triple drug combination.39
Safety evaluation
Cumulative experience with the two BRAFi, vemurafenib 
and dabrafenib, has shown that, although some toxicities 
such as skin toxicity, joint pain, and fever are common with 
both inhibitors, their type and severity vary considerably 
and may influence the choice of the drug (Table 2). For 
example, photosensitivity is common in patients treated 
with vemurafenib and much less frequent in patients treated 
with dabrafenib, whereas fever and chills are much more 
frequent with dabrafenib treatment. Skin toxicities are the 
most common AEs associated with BRAFi, experienced by up 
to 57% of patients, and appearing within days after therapy 
initiation (Figures 1–4).
Overall, dabrafenib is well tolerated by the patients, 
including those with brain metastases, since its side effects 
are common but usually manageable. The toxicities in the 
Phase III trial were similar to those observed in early-phase 
trials.11 The most common grade 2 or higher AEs were 
cutaneous manifestations (hyperkeratosis, papillomas, 
palma-plantar erythrodysesthesia), pyrexia, fatigue, head-
ache, and arthralgia. In the BREAK-3 trial,11 7% of patients 
developed cSCC/KA, three patients (2%) developed new 
primary melanomas, while phototoxicity was rare (3%), as 
were grade 3 AEs. Dose reductions were necessary in 28% 
Table 2 Skin toxicity
Vemurafenib Dabrafenib
Rash: 49% Hyperkeratosis: 39%
Photosensitivity: 31% Photosensitivity: rare
SCC: 19% SCC: 10%
Alopecia: 26% Alopecia: rare
Others (pruritus, dry skin,  
papillomas): frequent
Others (pruritus, dry skin, 
papillomas): not frequent
Abbreviation: SCC, squamous cell carcinoma including keratoacanthoma.
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of patients, and therapy was permanently discontinued due 
to toxicity in only 3% of patients. In the BREAK-MB study, 
82% of patients experienced at least one grade 2 or higher 
side effect and 22% had grade 3 or higher AE. However, 
only 2% discontinued dabrafenib due to toxicity.
Although vemurafenib is considered to be well toler-
ated as well, adverse effects are frequent, with skin toxicity 
representing the most common problem. Among several 
skin AEs reported in the literature, the most common are 
alopecia, photosensitivity, pruritus, hand–foot skin reactions 
(HFSR), cutaneous manifestations resembling hyperkeratotic 
and dyskeratotic diseases (Figure 1), follicular-centered 
eruption resembling keratosis pilaris (Figure 2),40 seborrheic 
dermatitis-like eruptions, and Darier or Grover-like erup-
tions. Less frequent events include pyogenic granuloma, 
gingival hyperplasia, and lupus erythematosus-like skin 
eruption.41–43
The development of keratosis pilaris-like eruptions 
associated with facial erythema and HFSR in patients treated 
with vemurafenib validate the association of facial erythema 
with the BRAF pathway and indicate VEGF inhibition as the 
molecular mechanism responsible for HFSR. The specific-
ity of vemurafenib for BRAF suggests that inhibition of the 
BRAF pathway alone is sufficient to induce HFSR.40 The 
occurrence of malignant and benign hyperproliferative skin 
lesions like cSCC, KA, warty dyskeratoma, and verrucous 
keratosis (Figure 3) has also been documented. The paradoxi-
cal phenomenon of vemurafenib-induced SCCs suggests that 
transformation of sensitive cells, harboring clinically silent 
RAS mutations, is regulated by BRAF-inhibitor-induced 
MAPK signaling via noninhibited RAF isoforms, highlight-
ing the complexity and redundancy of kinase signaling.44 
Notably, cSCCs and KAs associated with vemurafenib 
therapy are easily treated by simple excision, without 
requiring discontinuation of vemurafenib. Another peculiar 
side effect of vemurafenib is the darkening of existing nevi 
and the appearance of new nevi within 2 months after drug 
initiation (Figure 4).45–47 Skin toxicities generally cannot be 
Figure 1 Acantholytic dyskeratosis.
Figure 2 Keratosis pilaris.
Figure 3 verrucous keratosis.
Figure 4 New and enlarging melanocytic nevi.
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prevented, but rarely require permanent discontinuation of 
the treatment, being usually adequately managed with dose 
modification and appropriate therapy.48,49
The absence of photosensitivity with dabrafenib and the 
lower frequency of cutaneous AEs suggest dabrafenib as an 
appropriate alternative treatment option for patients who are 
intolerant to vemurafenib due to skin toxicity.
The combination of dabrafenib plus trametinib and vemu-
rafenib plus cobimetinib resulted in similar clinical efficacy. 
Therefore, the selection of combination regimen might 
mainly be based on its expected toxicity. Pyrexia is the most 
frequent AE reported with the combination of dabrafenib and 
trametinib (51%–53%; G3: 4%–6%), representing the most 
common reason for dose interruptions, dose reductions, and 
permanent discontinuation.34,35,37 No baseline features have 
been identified to predict pyrexia, and it does not seem to be 
associated with the clinical outcome.50 Other frequent AEs 
include fatigue (35%), nausea (30%–35%), headache (30%), 
chills (30%–31%), diarrhea (24%–32%), arthralgia (24%), 
rash (22%–23%), and hypertension (22%).34,35,37
Cardiac-related AEs may occur when trametinib is admin-
istered as a single agent or in combination with dabrafenib. 
Specifically, trametinib has been reported to decrease LVEF. 
In clinical trials, the median time to the first occurrence of left 
ventricular dysfunction, cardiac failure, and LVEF decrease 
was between 2 and 5 months. Integrated safety data from 
COMBI-D (N=209) and COMBI-V studies (N=559) sug-
gest a decreased ejection fraction as a common AE, whereas 
LVEF dysfunction and cardiac failure were not reported 
during COMBI-D, but were noted as uncommon events in 
the integrated safety analysis.
Pyrexia was reported also in patients treated with the 
combination of vemurafenib and cobimetinib, although to 
a much lesser extent as regarding frequency and severity 
(26%; G3: 2%).51 On the other hand, photosensitivity reaction 
(28%), diarrhea (56%; G3: 6%), increased aspartate/alanine 
aminotransferase (22%–23%; G3: 8%–11%) and increased 
creatinine kinase (27%; G3: 7%) are more frequent and 
severe with vemurafenib plus cobimetinib than dabrafenib 
plus trametinib. Ocular toxicity is also more commonly 
reported in patients treated with vemurafenib and cobimetinib 
(chorioretinopathy: 1%), though most of these events were 
low-grade and reversible without any treatment, or with dose 
reduction/withdrawal of cobimetinib.52
The most striking safety difference between combination 
therapy and monotherapy is the decreased incidence of 
new skin cancers and other hyperproliferative skin lesions. 
As discussed earlier, this finding is consistent with the 
suggested pathogenesis of these tumors, which includes a 
paradoxical activation of the MAPK pathway with upstream 
activation of signaling by preexisting RAS mutation.53 The 
addition of an MEK inhibitor leads to a block of RAS sig-
naling along the MAPK pathway and prevents the cellular 
proliferation.
Conclusion
BRAF inhibitors (vemurafenib and dabrafenib) have become 
worldwide standards of care for patients with BRAF-mutant 
metastatic melanoma, especially those with high tumor 
burden or progression after immunotherapy. Both agents 
improve survival, compared with chemotherapy, and have 
acceptable toxicity profiles. Combined BRAF and MEK inhi-
bition achieves a statistically significant further improvement 
in response rate, PFS, and OS compared to monotherapy. 
However, the majority of the patients develop resistance 
and tumor progression similar to that observed with BRAF 
inhibitor monotherapy. Preclinical evidence, a Phase I trial,45 
reported promising data indicating that a multitargeted 
upfront approach, including immunotherapy, might have the 
potential to achieve the greatest survival benefit for patients 
with metastatic melanoma.
Definitely, the appropriate selection of systemic therapy 
for metastatic melanoma remains an evolving field and 
requires further elucidation. For instance, long-term data 
on the combination therapy with dabrafenib and trametinib 
revealed that long-term survival and durable responses are 
associated with good prognostic features at baseline, includ-
ing factors related to low-volume disease.54 However, such 
baseline factors are classically considered a reason to choose 
front-line immunotherapy. The need to develop specific 
predictive molecular markers for each therapy is now more 
important than ever. Another issue requiring further clarifica-
tion is the determination of the optimal sequence of adminis-
tered therapeutic agents, since it remains unknown whether 
treating patients with ipilimumab and nivolumab followed 
by dabrafenib and trametinib is more effective than treatment 
with dabrafenib and trametinib followed by ipilimumab and 
nivolumab (ongoing trial NCT02224781).
Finally, neoadjuvant BRAF-targeted therapy in advanced 
locoregional BRAFV600 mutant melanoma patients rep-
resents a novel challenge to be addressed, with a relevant 
clinical trial urgently required.
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